

10/02/60

Please type a sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/05 (11-00)

Approved for use through 10/31/2002 OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Applicant claims small entity status.
See 37 CFR 1.27.
- Specification [Total Pages: 252]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed Sponsored R & D
 - Reference to Sequence Listing, a table, or a computer program listing appendix;
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- Informal Drawing(s) (35 U.S.C. 113) [Total Sheets: 2]
- Oath or Declaration [Total Pages: 6]
 - Newly executed (original or copy)
 - Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76. [Total Pages: 3]

Attorney Docket No.	PB324D1
First Inventor	Dillon et al.
Title	Nucleotide Sequence of Escherichia coli Pathogenicity Islands
Express Mail Label No.	

Commissioner for Patents Box Patent Application Washington, DC 20231
--

ADDRESS TO:

7. CD-ROM or CD-R in duplicate, large table or Computer Program (appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - Computer Readable Form (CRF)
 - Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper [Total Pages: 179]
- c. Statements verifying identity of above copies [Total Pages: 1]

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
11. English Translation Document (if applicable)
12. Information Disclosure Statement/ Form PTO/SB/08
 - Copies of Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
 - (should be specifically itemized)
15. Certified Copy of Priority Document(s)
 - (if foreign priority is claimed)
16. Other: (a) Submission of Formal Drawings with Formal Drawings of Figures 1-2 (2 sheets);
(b) Copy of Associate Power of Attorney from Application Serial No. 08/976,259

1c821 U.S. PTO
10/07/95 00:01

09/20/01

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-Part (CIP) of prior application No: 08/976,259

Prior application information: Examiner: Sorbello, E. Group/Art Unit: 1633

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label **22195** or Correspondence address below

NAME			
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	
NAME (Print/Type)	Registration No. (Attorney/Agent) 40,302		
SIGNATURE	Date <u>September 20, 2001</u>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231



FEET TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Total amount of payment

\$1,344.00

Complete if Known	
Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Dillon et al.
Examiner Name	To be assigned
Group Art Unit	To be assigned
Attorney Docket Number	PB324D1

METHOD OF PAYMENT

The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

Charge Any Additional Fee Required
Under 37 CFR §§ 1.16 and 1.17
 Applicant claims small entity status.
See 37 CFR 1.27

2. Payment Enclosed:

Check Credit Card Money Order Other*

FEES CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	\$710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) **\$710.00**

2. EXTRA CLAIM FEES

Extra Claims	Fee from below	Fee Paid
Total Claims 33	-20	13 \$18.00 \$234.00
Independent Claims 8	-3*	5 \$80.00 \$400.00

Multiple Dependent

\$270.00

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
108	80	209	40	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) **\$634.00**

** or number previously paid, if greater. For Reissues, see above

FEES CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
129	130	139	130	Non-English specification	
147	2,520	147	2,520	Filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to final action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive -unavoidable	
141	1,240	241	620	Petition to revive -unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	481	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify):					
Other fee (specify):					
Other fee (specify):					
SUBTOTAL (3) \$0.00					

* Reduced by Basic Filing Fee Paid

Submitted By

Name (Print/Type) **Kenley K. Hoover**

Signature:

Complete (if applicable)

Registration No.: **40,302**

Telephone **301-610-5771**

Date **September 26, 2001**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on FTO-203.

BUreau Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

VIA HAND DELIVERY SEPTEMBER 20, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: DILLON et al.

Application Number: To be assigned

Group Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

Title: Nucleotide Sequence of
Escherichia coli Pathogenicity Islands.

Attny. Docket No.: PB324D1

STATEMENT UNDER 37 C.F.R. § 1.821

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: September 20, 2001


Kenley K. Hoover Reg. No. 40,302
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: 301-610-5771

Enclosures

KKH/MJH/BM

VIA HAND DELIVERY SEPTEMBER 20, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: DILLON et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: Nucleotide Sequence of *Escherichia Coli*
Pathogenicity Islands

Atty. Docket No.: PB324D1

SUBMISSION OF FORMAL DRAWINGS

Commissioner for Patents
Washington, D.C. 20231

To the Official Draftsperson:

Applicants submit herewith Formal Drawings of Figures 1-2 (two sheets) to replace the informal drawings of Figures 1-2 (two sheets).

No fee is believed due for this submission. In the event that a fee is required in connection with this submission, please charge the required fee to Deposit Account No. 08-3425.

Respectfully submitted,

Dated: September 20, 2001

Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5771

Enclosures

KKH/MJH/BM/